NBSE
NeuBase Therapeutics Inc
NeuBase Therapeutics Inc historical holders
total: 1
Greenlight Capital NeuBase Therapeutics Inc transactions over time
- Total transactions:
- 6
- New positions:
- 1
- Sold out:
- 1
- Added:
- 3
- Reduced:
- 1
- Held since:
- 2019 Q3
- Held for:
- 19 quarters
- Latest activity:
- 2024 Q2
David Einhorn has been an institutional investor in NeuBase Therapeutics Inc (NBSE) since 2019 Q3. According to 2026 Q2 report, David Einhorn doesn't hold any shares. The fund/company first acquired NBSE in 2019 Q3, initially purchasing 76,923 shares. Since the initial investment, Greenlight Capital has made 5 more transactions in this position.
When did David Einhorn exit their NBSE position?
David Einhorn no longer holds NeuBase Therapeutics Inc (NBSE). They sold off their entire position in 2024 Q2, closing out an investment that began in 2019 Q3.
When did David Einhorn first invest in NBSE?
David Einhorn first invested in NeuBase Therapeutics Inc (NBSE) in 2019 Q3 at the reported quarter-end price of $99.80 per share, acquiring 76,923 shares in their initial purchase.
What is David Einhorn's average cost basis for NBSE?
Based on historical transaction data, David Einhorn's estimated cost basis for NeuBase Therapeutics Inc (NBSE) is approximately $111.27 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $111.27
- Weighted AVG sell price:
- $0.45
NBSE transactions history by Greenlight Capital
6 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2024 Q2
|
0.00%
|
0
|
$0.45
|
|
-100% (-136,350)
|
-0%
|
|
2023 Q2
|
0.01%
|
136,350
|
$1.87
|
$254,975
|
-0.00% (-1.35)
|
0%
|
|
2021 Q2
|
0.82%
|
136,351.35
|
$95.80
|
$13,062,000
|
+34.53% (+35,000)
|
+0.21%
|
|
2020 Q3
|
1.27%
|
$151.81
|
+6.50% (+6,190)
|
|||
|
2020 Q2
|
1.83%
|
$175.61
|
+23.71% (+18,238.25)
|
|||
|
2019 Q3
|
0.55%
|
$99.80
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.